Key result
EuroSCORE II and STS score independently predicted 30-day and cumulative mortality in TAVI patients, but these associations were significant only in those undergoing transapical TAVI.
Why the study?
Do the EuroSCORE II and STS score accurately predict 30-day and cumulative mortality in patients undergoing transapical versus transfemoral TAVI?
Cohort (n=1,192)
Yes
Do the EuroSCORE II and STS score accurately predict 30-day and cumulative mortality in patients undergoing transapical versus transfemoral TAVI?
The EuroSCORE II and STS score are valid predictors of short- and long-term mortality in patients undergoing transapical TAVI, but lack predictive accuracy for transfemoral TAVI.
Answers are grounded in this paper and cite their sources.
Risk scores show uncertain predictive value for TAVI mortality; leaves open need for dedicated TAVI models and prospective confirmation.
OBJECTIVES: The European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and the Society of Thoracic Surgeons (STS) score are currently used to estimate periprocedural risk of death in patients undergoing transcatheter aortic valve implantation (TAVI). However, data regarding the predictive ability and usefulness of these scores for TAVI are controversial, especially for different access sites. METHODS: Between 2008 and 2016, 1192 consecutive patients undergoing TAVI [transfemoral (TF): n = 607 (51%); transapical (TA): n = 585 (49%)] at 2 centres were included. All-cause mortality was assessed at a median of 533 days (interquartile range 153-1036). The value of the EuroSCORE II and the STS score in terms of predicting 30-day and cumulative mortality according to access site was investigated. RESULTS: The mean age was 83 (interquartile range 79-86) years. Overall, the 30-day mortality rate was 7.6% (n = 90), and the cumulative all-cause mortality rate was 35.1% (n = 418). The EuroSCORE II and the STS score were significantly increased in non-survivors compared with survivors (P < 0.001). The EuroSCORE II and the STS score emerged as independent predictors of 30-day mortality [EuroSCORE II: odds ratio (OR) 1.039, 95% confidence interval (CI) 1.013-1.065; P = 0.003; STS score: OR 1.055, 95% CI 1.023-1.088; P = 0.001] and cumulative all-cause mortality [EuroSCORE II: hazard ratio (HR) 1.026, 95% CI 1.013-1.038; P < 0.001; STS score: HR 1.05, 95% CI 1.03-1.06; P < 0.001]. In contrast to TF TAVI, the EuroSCORE II (OR 1.038, 95% CI 1.009-1.068; P = 0.010) and the STS score (OR: 1.063, 95% CI 1.025-1.102; P = 0.001) were independent predictors of 30-day mortality and cumulative mortality (EuroSCORE II: HR 1.023, 95% CI 1.009-1.037; P = 0.001; STS score: HR 1.055, 95% CI 1.037-1.073; P < 0.001) in patients undergoing TA TAVI. CONCLUSIONS: The EuroSCORE II and the STS score were independent predictors of 30-day and cumulative mortality rates in patients undergoing TAVI. The EuroSCORE II and the STS score were associated with 30-day mortality and mortality during follow-up period only in TA TAVI.
No takes yet. Share an insight, caveat, or question.
Kofler et al. (2017) conducted a cohort in Patients undergoing transcatheter aortic valve implantation (TAVI) (n=1,192). EuroSCORE II and STS score was evaluated on 30-day mortality (OR 1.039, 95% CI 1.013-1.065, p=0.003). EuroSCORE II and STS score independently predicted 30-day and cumulative mortality in TAVI patients, but these associations were significant only in those undergoing transapical TAVI.
Synapse has enriched 10 related papers. Consider them for comparative context: